6 results about "CD68" patented technology

The application belongs to the technical field of medical treatment and discloses a cancer prognosis marker combination and application thereof, which comprises the following markers: CD68, PD-L1, PAN-CK, HLA-DR, CD45, CD11c and Collagen I. The cancer prognosis evaluation model trained by using the 7-marker combination exhibits superior prognosis accuracy compared to a model relying on high-dimensional multi-omics data. The application proposes a multiple immunohistochemistry (mIHC) cancer prognosis evaluation detection product based on the above-mentioned cancer prognosis marker combination. Satisfactory prognosis results are achieved by using only two five-marker combinations. The method exhibits high accuracy in predicting the survival of gastric cancer patients, so that it becomes a low-cost, high-benefit and scalable solution for other cancers.

The application relates to the field of biological medicine, in particular to an anti-CD68 antibody and preparation and application thereof, wherein the anti-CD68 antibody has heavy chain complementarity determining regions 1-3 as shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 respectively, and light chain complementarity determining regions 1 and 3 as shown in SEQ ID NO:4 and SEQ ID NO:5 respectively, and a light chain complementarity determining region 2 with LVS. Compared with the CD68 antibody proposed in the related art, the anti-CD68 antibody proposed in the application has stronger binding specificity to CD68 and lower reaction background, thereby realizing high-accuracy detection of CD68.

The present disclosure relates to methods of treating certain cancers with a Siglec-9 extracellular domain (ECD) or a Siglec-9 ECD fusion molecule, including cancers expressing high levels of CD163 and / or Siglec-9 in tumor or immune cells, and methods of identifying cancers responsive to a Siglec-9 ECD or Siglec-9 ECD fusion molecule, for example by determining the level of CD163 and / or Siglec-9, and in some embodiments also CD68 and / or sialic acid expression in tumor or immune cells.

The invention discloses a prognostic marker for bladder cancer and application of the prognostic marker. The prognostic marker for the bladder cancer comprises CD14T, CD68S, CD163T and S100A12S; wherein the CD14T and the CD163T respectively refer to CD14 and CD163 expressed in a bladder cancer tumor region, and the CD68S and the S100A12S respectively refer to CD68 and S100A12 expressed in a bladder cancer matrix region. The bladder cancer prognosis marker provided by the invention can be used for constructing a bladder cancer prognosis prediction model, and multi-queue verification proves that the model has a strong prediction capability on the postoperative survival condition of a BLC patient and is beneficial to postoperative risk assessment and clinical decision of the BLC patient.

The application discloses application of GPER1 and CD68 as a prognostic marker in preparation of a hepatocarcinoma prognosis test kit. Researches of the application show that by detecting the expression of GPER1 in macrophages of hepatocarcinoma tissues, the survival prognosis of hepatocarcinoma patients can be more accurately predicted. Specifically, a double immunofluorescence staining combined with tyramide signal amplification technology is used to detect the co-expression proportion of GPER1 and CD68 in hepatocarcinoma tissues, and it is shown that the prediction effect of the hepatocarcinoma patients on overall survival and recurrence-free survival is better than the overall GPER1 expression of tumor tissues. Compared with the prior art (only immunohistochemical staining of GPER1 is performed on tumor tissues), the method can obtain more detailed and accurate information of the GPER1 protein expression mode, and the prediction effect on the survival of hepatocarcinoma patients is better; the method is simple and easy to operate, and ordinary technicians can complete the whole operation process.

This invention relates to an anti-human CD68 monoclonal antibody, its preparation method, and its applications. The amino acid sequences of the heavy chain complementarity-determining regions (CDR1, CDR2, and CDR3) of the anti-human CD68 monoclonal antibody include the sequences shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively, and the amino acid sequences of the light chain complementarity-determining regions (CDR1, CDR2, and CDR3) include the sequences shown in SEQ ID NO.4, SEQ ID NO.5, and SEQ ID NO.6, respectively. This invention develops and prepares a highly specific and affinity-based anti-human CD68 monoclonal antibody with good anti-interference ability, wide applicability, and is suitable for high-specificity, high-accuracy, and high-sensitivity detection of CD68, especially for immunohistochemical detection.